Indications
Therapeutic Asset Ratings
9,922 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Naptumomab Estafenatox
Cervical Squamous Cell Carcinoma
NeoTX Therapeutics Ltd.
P1
CC
(43)
Naptumomab Estafenatox
Estrogen-Receptor Positive Breast Cancer
NeoTX Therapeutics Ltd.
P1
CC
(43)
Navitoclax
Ovarian Serous Adenocarcinoma
Sunnybrook Health Sciences Centre
P1
CC
(43)
Navitoclax
Myeloid Neoplasm
Jacqueline Garcia, MD
P1
CC
(43)
nc525
Acute Myeloid Leukemia
NextCure, Inc.
P1
CC
(43)
nc525
Chronic Myelomonocytic Leukemia
NextCure, Inc.
P1
CC
(43)
Ncp-Cd47 Sirna Intratumorally
Metastatic Neoplasm
West China Hospital
P1
CC
(43)
Neldaleucel
Non-Hodgkin Lymphoma
Marker Therapeutics, Inc.
P1
CC
(43)
Neoantigen Personalized Cancer Vaccine
Digestive System Neoplasm
Ruijin Hospital
P1
CC
(43)
Neoantigen Personalized Cancer Vaccine
Neoplasm
Ruijin Hospital
P1
CC
(43)
Neovax
Lymphoid Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Neratinib
Amyotrophic Lateral Sclerosis Type 19
M.D. Anderson Cancer Center
P1
CC
(43)
Neural Stem Cells-Expressing Crad-S-Pk7
Glioblastoma
City of Hope Medical Center
P1
CC
(43)
Neurotop
Isolated Focal Cortical Dysplasia
GRIN Therapeutics, Inc.
P1
CC
(43)
Neurotop
Nervous System Disorder
GRIN Therapeutics, Inc.
P1
CC
(43)
Newly Matched Donor-Derived Fl-33 Car T Therapy
Acute Myeloid Leukemia
Beijing GoBroad Hospital
P1
CC
(43)
ngm438
Bladder Transitional Cell Carcinoma
NGM Biopharmaceuticals, Inc
P1
CC
(43)
ngm438
Endocervical Carcinoma
NGM Biopharmaceuticals, Inc
P1
CC
(43)
ngm831
Bladder Transitional Cell Carcinoma
NGM Biopharmaceuticals, Inc
P1
CC
(43)
ngm831
Endocervical Carcinoma
NGM Biopharmaceuticals, Inc
P1
CC
(43)
Nintedanib
Acute Myeloid Leukemia With 11q23 Abnormalities
Northwestern University
P1
CC
(43)
Nintedanib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
Northwestern University
P1
CC
(43)
Nintedanib
Interstitial Lung Disease
Shenzhen Resproly Biopharmaceutical Co., Ltd
P1
CC
(43)
Niraparib
Familial Ovarian Carcinoma
University of Washington
P1
CC
(43)
Niraparib
Hereditary Breast Carcinoma
University of Washington
P1
CC
(43)
Showing 2901 to 2925 of 9,922 assets
Previous
Page 117 of 397
Next